← Leaderboards
John N Van Den Anker
Research Inst Nationwide Children'S Hosp
$10,613,410
Attributed
$13,137,220
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$18,327,128 · 21
FDA$3,000,000 · 1
By mechanism
U54$7,115,918 · 3
R01$3,002,346 · 2
U18$3,000,000 · 1
U10$2,552,113 · 1
P50$2,140,111 · 2
K24$1,585,046 · 2
Top collaborators
- Christopher B Forrest3 shared
- Collin Hovinga3 shared
- Peter A Margolis3 shared
- Gary J. Noel3 shared
- Robert Marshall Ward3 shared
- Martha A Brumfield1 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DosePharmaceutical PreparationsClinical TrialsBaseChildhoodDrug KineticsPediatric PharmacologyResearch PersonnelChildProgramsNeonateInfantInvestigationPharmacodynamicsMedicineMetabolismPainFundingSafetyGrowthAdultUrineClinical PharmacologyClinical Research
Grant awards (62)
I-ACT for Children, Global Pediatric Clinical Trials Network$1,000,000
U18 · FY2021 · FD
I-ACT for Children, Global Pediatric Clinical Trials Network$1,000,000
U18 · FY2020 · FD
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases$816,558
P50 · FY2020 · HD · contact PI
Administrative Core$245,013
P50 · FY2020 · HD · contact PI
Postdoctoral training in Pediatric Clinical Pharmacology$124,804
T32 · FY2020 · HD · contact PI
I-ACT for Children, Global Pediatric Clinical Trials Network$1,000,000
U18 · FY2019 · FD
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases$824,198
P50 · FY2019 · HD · contact PI
Administrative Core$254,342
P50 · FY2019 · HD · contact PI
Postdoctoral training in Pediatric Clinical Pharmacology$205,836
T32 · FY2019 · HD · contact PI
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases$830,032
U54 · FY2018 · HD · contact PI
Postdoctoral training in Pediatric Clinical Pharmacology$274,375
T32 · FY2018 · HD · contact PI
Administrative Core$245,012
U54 · FY2018 · HD · contact PI
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases$834,222
U54 · FY2017 · HD · contact PI
Postdoctoral training in Pediatric Clinical Pharmacology$265,882
T32 · FY2017 · HD · contact PI
Administrative Core$160,877
U54 · FY2017 · HD · contact PI
Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases$841,359
U54 · FY2016 · HD · contact PI
Administrative Core$160,877
U54 · FY2016 · HD · contact PI
Postdoctoral training in Pediatric Clinical Pharmacology$127,355
T32 · FY2016 · HD · contact PI
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense$807,794
U54 · FY2015 · HD · contact PI
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense$785,176
U54 · FY2014 · HD · contact PI
Metabolism and Toxicity of Acetaminophen in Preterm Infants$292,626
R01 · FY2014 · HD · contact PI
Optimizing the Use of Methadone in Newborn Infants$170,380
K24 · FY2014 · DA · contact PI
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense$766,596
U54 · FY2013 · HD · contact PI
Metabolism and Toxicity of Acetaminophen in Preterm Infants$285,105
R01 · FY2013 · HD · contact PI
Optimizing the Use of Methadone in Newborn Infants$170,370
K24 · FY2013 · DA · contact PI
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense$807,792
U54 · FY2012 · HD · contact PI
Metabolism and Toxicity of Acetaminophen in Preterm Infants$301,050
R01 · FY2012 · HD · contact PI
Optimizing the Use of Methadone in Newborn Infants$170,359
K24 · FY2012 · DA · contact PI
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense$876,181
U54 · FY2011 · HD · contact PI
Metabolism and Toxicity of Acetaminophen in Preterm Infants$319,985
R01 · FY2011 · HD · contact PI
Optimizing the Use of Methadone in Newborn Infants$183,417
K24 · FY2011 · DA · contact PI
Metabolism and Toxicity of Acetaminophen in Preterm Infants$344,460
R01 · FY2010 · HD · contact PI
Optimizing the Use of Methadone in Newborn Infants$183,405
K24 · FY2010 · DA · contact PI
ANTIMICROBIAL PHARMACOKINETICS IN HIGH RISK INFANTS$4,893
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: OPTIMIZING PAIN TREATMENT IN PRE-TERM NEONATES$1,468
M01 · FY2010 · RR · contact PI
MULTIPLE DOSE PHARMACOKINETIC STUDY OF MEROPENEM IN YOUNG INFANTS (91 DAYS)$979
M01 · FY2010 · RR · contact PI
Washington D.C. Collaborative PPRU$298,830
U10 · FY2009 · HD · contact PI
Optimizing the Use of Morphine in Preterm Infants$257,500
R01 · FY2009 · HD · contact PI
CLINICAL TRIAL: OPTIMIZING PAIN TREATMENT IN PRE-TERM NEONATES$3,499
M01 · FY2009 · RR · contact PI
Washington D.C. Collaborative PPRU$530,757
U10 · FY2008 · HD · contact PI
Optimizing the Use of Morphine in Preterm Infants$293,640
R01 · FY2008 · HD · contact PI
Optimizing Pain Treatment in the Preterm Infant$141,423
K24 · FY2008 · RR · contact PI
OPTIMIZING PAIN TREATMENT IN PRE-TERM NEONATES$8,147
M01 · FY2008 · RR · contact PI
PREVALENCE OF PROTEINURIA IN OVERWEIGHT ADOLESCENTS$684
M01 · FY2008 · RR · contact PI
Washington D.C. Collaborative PPRU$530,459
U10 · FY2007 · HD · contact PI
Optimizing the Use of Morphine in Preterm Infants$295,620
R01 · FY2007 · HD · contact PI
Optimizing Pain Treatment in the Preterm Infant$141,423
K24 · FY2007 · RR · contact PI
OPTIMIZING PAIN TREATMENT IN PRE-TERM NEONATES$3,782
M01 · FY2007 · RR · contact PI
PREVALENCE OF PROTEINURIA IN OVERWEIGHT ADOLESCENTS$318
M01 · FY2007 · RR · contact PI
Washington D.C. Collaborative PPRU$370,798
U10 · FY2006 · HD · contact PI
Optimizing the Use of Morphine in Preterm Infants$298,260
R01 · FY2006 · HD · contact PI
Optimizing Pain Treatment in the Preterm Infant$141,423
K24 · FY2006 · RR · contact PI
Non-invasive Assessment of Opiate Analgesia in Children with Sickle Cell Disease$82,192
U10 · FY2006 · HD · contact PI
Washington D.C. Collaborative PPRU$375,000
U10 · FY2005 · HD
Optimizing the Use of Morphine in Preterm Infants$314,100
R01 · FY2005 · HD
Optimizing Pain Treatment in the Preterm Infant$141,423
K24 · FY2005 · RR
OPTIMIZING PAIN TREATMENT IN PRE-TERM NEONATES$19,414
M01 · FY2005 · RR
Washington D.C. Collaborative PPRU$364,077
U10 · FY2004 · HD
Optimizing Pain Treatment in the Preterm Infant$141,423
K24 · FY2004 · RR
NETWORK OF PEDIATRIC PHARMACOLOGY RESEARCH UNITS$349,464
U01 · FY2002 · HD
PEDIATRIC PHARMACOLOGY RESEARCH UNIT$341,415
U01 · FY2001 · HD
PEDIATRIC PHARMACOLOGY RESEARCH UNIT$199,279
U01 · FY2000 · HD